180 Life Sciences Corp.: management transactions · United States · SEC (Form 4)

About 180 Life Sciences Corp.

180 Life Sciences Corp. (ticker: ATNF) is a US-listed company traded on the NASDAQ Capital Market in the United States, with its operating base in Palo Alto, California. The company’s roots are in clinical-stage biotechnology: it was originally formed as a Delaware blank-check company in 2016 and completed its business combination on November 6, 2020, at which point it adopted the 180 Life Sciences Corp. name and transitioned into a science-driven operating business. Over time, however, the company has materially broadened — and in practice changed — its strategic profile. Historically, 180 Life Sciences was built around therapeutic programs targeting chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its early research strategy emphasized anti-TNF approaches and, in certain cases, cannabidiol-derived compounds and combination therapies. That original positioning made the company a classic development-stage biotech: highly dependent on preclinical or early clinical progress, intellectual property protection, and future financing rather than current product revenue. In other words, the investment case was based on scientific optionality and pipeline value rather than a mature commercial footprint. In the last couple of years, the company has announced a strategic pivot toward the global iGaming sector while still referencing its legacy biotechnology assets. In 2024 and 2025, management highlighted a new direction centered on digital gaming technology and platform development, alongside continued work on legacy IP. For investors, this is an important distinction: ATNF should no longer be viewed as a pure-play biotech. It is better understood as a transition story, with one leg in life sciences and another in digital entertainment / iGaming, which substantially changes the risk profile, capital allocation needs, and valuation framework. From a competitive standpoint, 180 Life Sciences remains a small, highly speculative public company rather than a scaled commercial leader. In biotech, it does not have the breadth of a large-cap pharmaceutical or late-stage clinical platform; in iGaming, it is still an emerging entrant rather than an established operator. Its potential advantages lie in strategic flexibility, public-market access, and the ability to monetize intellectual property or newly acquired technology assets. At this stage, the company’s offering is best described as a portfolio of development initiatives rather than a fully mature product suite. Geographically, the company is anchored in Palo Alto, California, United States, and its public disclosures continue to emphasize that base. Recent corporate milestones include regaining compliance with Nasdaq listing requirements in 2024 and completing a large private placement in 2025, signaling both improved market access and meaningful dilution risk. For French-speaking investors, ATNF should therefore be approached as a turnaround / transformation name with high execution risk and potentially high upside if its strategic pivot and legacy assets produce material value.